ProMIS Neurosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference
ProMIS Neurosciences (Nasdaq: PMN), a biotechnology company focused on developing therapeutics for neurodegenerative diseases, announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. CEO Neil Warma will present an overview of the company's antibody therapeutics targeting toxic misfolded proteins in diseases like Alzheimer's, ALS, and multiple system atrophy.
Key points:
- Presentation available on-demand from September 9, 2024, at 7:00 a.m. ET
- One-on-one meetings with investors scheduled for September 9-10, 2024
- Replay accessible for at least 30 days on the company's website
This event provides an opportunity for ProMIS to showcase its innovative approach to treating neurodegenerative diseases to potential investors and industry professionals.
ProMIS Neurosciences (Nasdaq: PMN), una compagnia biotecnologica focalizzata nello sviluppo di terapie per le malattie neurodegenerative, ha annunciato la sua partecipazione al 26° Congresso Annuale Globale sugli Investimenti H.C. Wainwright. Il CEO Neil Warma presenterà una panoramica delle terapie con anticorpi mirate a proteine tossiche mal ripiegate in malattie come l'Alzheimer, la SLA e l'atrofia multipla di sistema.
Punti chiave:
- Presentazione disponibile on-demand dal 9 settembre 2024 alle 7:00 a.m. ET
- Incontri one-to-one con gli investitori programmati per il 9-10 settembre 2024
- Riproduzione accessibile per almeno 30 giorni sul sito web della compagnia
Questo evento offre a ProMIS l'opportunità di mostrare il suo approccio innovativo al trattamento delle malattie neurodegenerative a potenziali investitori e professionisti del settore.
ProMIS Neurosciences (Nasdaq: PMN), una empresa biotecnológica centrada en el desarrollo de terapias para enfermedades neurodegenerativas, anunció su participación en la 26ª Conferencia Anual Global de Inversión H.C. Wainwright. El CEO Neil Warma presentará una visión general de las terapias con anticuerpos dirigidas a proteínas mal plegadas tóxicas en enfermedades como Alzheimer, ELA y atrofia multisistémica.
Puntos clave:
- Presentación disponible bajo demanda desde el 9 de septiembre de 2024 a las 7:00 a.m. ET
- Reuniones uno a uno con inversores programadas para el 9-10 de septiembre de 2024
- Repetición accesible durante al menos 30 días en el sitio web de la empresa
Este evento ofrece a ProMIS la oportunidad de mostrar su enfoque innovador para tratar enfermedades neurodegenerativas a posibles inversores y profesionales de la industria.
ProMIS Neurosciences (Nasdaq: PMN)는 신경퇴행성 질환 치료제를 개발하는 데 중점을 두고 있는 생명공학 기업으로, H.C. Wainwright 제26회 연례 글로벌 투자 회의에 참여한다고 발표했습니다. CEO Neil Warma는 알츠하이머, ALS, 다계통 위축증과 같은 질환에서 독성 단백질 접힘 이상을 목표로 하는 항체 치료제에 대한 개요를 발표할 예정입니다.
주요 사항:
- 2024년 9월 9일 오전 7:00 ET부터 주문형 발표 가능
- 2024년 9월 9-10일에 투자자와의 일대일 미팅 예정
- 회사 웹사이트에서 최소 30일 동안 재생 가능
이번 행사는 ProMIS가 신경퇴행성 질환 치료에 대한 혁신적인 접근 방식을 잠재 투자자와 업계 전문가에게 선보일 수 있는 기회를 제공합니다.
ProMIS Neurosciences (Nasdaq: PMN), une entreprise de biotechnologie axée sur le développement de thérapies pour les maladies neurodégénératives, a annoncé sa participation à la 26e Conférence Annuelle Mondiale sur l'Investissement H.C. Wainwright. Le PDG Neil Warma présentera un aperçu des thérapies par anticorps ciblant les protéines mal repliées et toxiques dans des maladies telles que la maladie d'Alzheimer, la SLA et l'atrophie multisystémique.
Points clés :
- Présentation disponible à la demande à partir du 9 septembre 2024 à 7 h 00 ET
- Réunions individuelles avec des investisseurs prévues pour le 9 et 10 septembre 2024
- Rediffusion accessible pendant au moins 30 jours sur le site Web de l'entreprise
Cet événement offre à ProMIS l'opportunité de présenter son approche innovante pour traiter les maladies neurodégénératives à de potentiels investisseurs et professionnels du secteur.
ProMIS Neurosciences (Nasdaq: PMN), ein biotechnologisches Unternehmen, das sich auf die Entwicklung von Therapeutika für neurodegenerative Erkrankungen konzentriert, gab seine Teilnahme an der 26. jährlichen globalen Investorenkonferenz von H.C. Wainwright bekannt. CEO Neil Warma wird eine Übersicht über die Antikörpertherapeutika präsentieren, die auf toxisch falsch gefaltete Proteine bei Erkrankungen wie Alzheimer, ALS und multiple Systematrophie abzielen.
Wichtige Punkte:
- Präsentation ab dem 9. September 2024 um 7:00 Uhr ET auf Anfrage verfügbar
- Einzelgespräche mit Investoren sind für den 9.-10. September 2024 geplant
- Wiederholung für mindestens 30 Tage auf der Unternehmenswebsite verfügbar
Diese Veranstaltung bietet ProMIS die Möglichkeit, seinen innovativen Ansatz zur Behandlung von neurodegenerativen Erkrankungen potenziellen Investoren und Fachleuten der Branche vorzustellen.
- None.
- None.
CAMBRIDGE, Massachusetts and TORONTO, Ontario, Sept. 05, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of therapeutics targeting toxic misfolded proteins in neurodegenerative diseases, today announced that Neil Warma, Chief Executive Officer of ProMIS Neurosciences, will participate at the H.C. Wainwright 26th Annual Global Investment Conference and will conduct one-on-one meetings from September 9 – 10, 2024.
Mr. Warma will deliver an overview of the Company’s pioneering antibody therapeutics that selectively target toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease, amyotrophic lateral sclerosis and multiple system atrophy (MSA) and will be available for virtual meetings with investors through the H.C. Wainwright conference platform.
The company’s presentation will be available to view on demand beginning Monday, September 9, 2024 at 7:00 a.m. Eastern Time by visiting the Events page of the Company’s website at www.promisneurosciences.com. The replay will be available for at least 30 days following the event.
About ProMIS Neurosciences Inc.
ProMIS Neurosciences Inc. is a clinical stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). The Company’s proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS™ and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this unique approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. ProMIS has offices in Cambridge, Massachusetts and Toronto, Ontario.
For further information:
Visit us at www.promisneurosciences.com
Please submit media inquiries to info@promisneurosciences.com.
For Investor Relations, please contact:
Precision AQ (formerly Stern IR)
Anne Marie Fields, Managing Director
annemarie.fields@precisionaq.com
Tel. 212-362-1200
FAQ
When is ProMIS Neurosciences (PMN) presenting at the H.C. Wainwright Global Investment Conference?
What will ProMIS Neurosciences (PMN) discuss in their presentation at the H.C. Wainwright conference?
How long will the replay of ProMIS Neurosciences' (PMN) presentation be available?
What is the focus of ProMIS Neurosciences' (PMN) research and development?
